anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Fever is a common symptom among travellers returning from tropical/subtropical areas to Europe, and promptly distinguishing severe illnesses from self-limiting febrile syndromes is important but can be challenging due to non-specific clinical presentation.
METHODS: A cross-sectional study enrolled adults and children who sought care during 2015-2020 at Karolinska University Hospital, Stockholm, Sweden with fever within 2 months after returning from travel to a tropical/subtropical area. Data on symptoms and laboratory parameters were prospectively and retrospectively collected. Two separate scoring systems for malaria and dengue were developed based on backward elimination regressions.
RESULTS: In total, 2113 adults (18-94 years) and 202 children (1-17 years) were included, with 112 (4.8%) confirmed malaria by blood thick smear and 90 (3.9%) PCR/serology dengue-positive cases. Malaria was more likely in a patient who had visited sub-Saharan Africa and presented with combination of thrombocytopenia, anaemia and fever ≥39.5°C. Leucopenia, muscle pain and rash after travelling to Asia or South/Latin America indicated high probability of dengue. Two scoring systems with points between 0 and 7 for prediction of malaria or dengue were created based on the above predictors. Scores ≥3 indicated >80% sensitivity and specificity for malaria and >90% specificity for dengue in children and adults (area under the curve (AUC) for dengue: 0.92 in adults (95% CI 0.90 to 0.95) and 0.95 in children (95% CI 0.88 to 1.0); AUC for malaria: 0.93 in adults (95% CI 0.91 to 0.96) and 0.88 in children (95% CI 0.78 to 0.99)). Internal validation of optimism and overfitting was managed with bootstrap.
CONCLUSION: The presented scoring systems provide novel tools for structured assessment of patients with tropical fever in a non-endemic area and highlight clinical signs associated with a potential severe aetiology to direct the need for microbial investigation.
Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive amphotericin B at a dose of 1 mg /kg/day for 14 days (chen et al.,2019).
RATIONALE: The bleeding of Dieulafoy lesion predominantly involves the proximal stomach and leads to severe gastrointestinal bleeding. However, these lesions have also been reported in the whole gastrointestinal tract. Bleeding of Dieulafoy lesions at the anastomosis was seldomly reported and was very easy to be ignored clinically.
PATIENT CONCERNS: We describe a 72-year-old woman with a past history of surgery for rectal carcinoma hospitalized with chief complaint of massive rectal bleeding. No gross bleeding lesion was found during the first emergency colonoscopy. Despite multiple blood transfusions, her hemoglobin rapidly dropped to 5.8 g/dL.
DIAGNOSIS: She was diagnosed with Dieulafoy lesion at the colorectal anastomosis during the second emergency colonoscopy.
INTERVENTIONS: Primary hemostasis was achieved by endoscopic hemostatic clipping. However, she experienced another large volume hematochezia 3 days later, and then received another endoscopic hemostatic clipping. She was improved and discharged. However, this patient underwent hematochezia again 1 month later. Bleeding was arrested successfully after the over-the-scope clip (OTSC) was placed during the fourth emergency colonoscopy.
OUTCOMES: This patient underwent 4 endoscopic examinations and treatments during 2 hospitalizations. The lesion was overlooked during the first emergency colonoscopy. The second and third endoscopes revealed Dieulafoy lesion at the colorectal anastomosis and performed endoscopic hemostatic clippings, but delayed rebleeding occurred. The bleeding was stopped after the fourth emergency colonoscopy using OTSC. There was no further rebleeding during hospitalization and after 2-year of follow-up.
LESSONS: As far as we know, there is no reported case of lower gastrointestinal bleeding caused by Dieulafoy lesion at the colorectal anastomosis, OTSC is a safe and effective rescue treatment for Dieulafoy lesions.
Washing and cleansing agents contain at least one cpd. of formula (I): (where Y is O, S or NH, R1 and R3 are H, halogen, lower alkyl, lower alkoxy, acyl, CN, NO2 or CF3, R2 is H, halogen, lower alkyl, lower alkoxy, acyl, CN or NO2, and B is a 3-12C (un)branced, (un)satd. aliphatic residue opt. interrupted by 1 or more O and/or S atoms, at least one of R1-R3 being other than H, and B not being an unbranched satd. aliphatic residue when R2 represents halogen other than Br.). (I) have antibacterial and antifungal activity, as well as anthelmintic, insecticidal and antiparasitic properties. They do not lose their activity in the presence of proteins and surface-active agents, have no disagreeable odour, are well tolerated by healthy skin, and have no toxic effects towards warm-blooded animals when used in the concns. usual in disinfection.
Despite remarkable progress in understanding the fundamental bases of itching, its cortical mechanisms remain poorly understood. Herein, the causal contributions of defined anterior cingulate cortex (ACC) neuronal populations to acute itch modulation in mice are established. Using cell type-specific manipulations, the opposing functions of ACC glutamatergic and GABAergic neurons in regulating acute itching are demonstrated. Photometry studies indicated that ACC glutamatergic neurons are activated during scratching induced by both histamine and chloroquine, whereas the activation pattern of GABAergic neurons is complicated by GABAergic subpopulations and acute itch modalities. By combining cell type- and projection-specific techniques, a thalamocortical circuit is further identified from the mediodorsal thalamus driving the itch-scratching cycle related to histaminergic and non-histaminergic itching, which is contingent on the activation of postsynaptic parvalbumin-expressing neurons in the ACC. These findings reveal a cellular and circuit signature of ACC neurons orchestrating behavioral responses to itching and may provide insights into therapies for itch-related diseases.
Few studies in the US address alcohol consumption patterns in adults with chronic health conditions, and little is known about race and ethnicity differences. This study examined at-risk drinking prevalence rates among US adults with hypertension, diabetes, heart condition or cancer and assessed differences by gender and, among adults aged 50 and older, by race and ethnicity. We used data from the 2015-2019 National Survey on Drug Use and Health (N = 209,183) to estimate (1) prevalence rates and (2) multivariable logistic regression models predicting odds of at-risk drinking among adults with hypertension, diabetes, heart condition, or cancer, compared to adults with none of these conditions. To examine subgroup differences, analyses were stratified by gender (ages 18-49 and ages 50 +) and by gender and race and ethnicity for adults ages 50 + . Results showed that all adults with diabetes and women ages 50 + with heart conditions in the full sample had lower odds of at-risk drinking relative to their counterparts without any of the four conditions. Men ages 50 + with hypertension had greater odds. In race and ethnicity assessments among adults ages 50 + , only non-Hispanic White (NHW) men and women with diabetes and heart conditions had lower odds, and NHW men and women and Hispanic men with hypertension had greater odds of at-risk drinking. There were differential associations of at-risk drinking with demographic and lifestyle indicators across race and ethnicity groups. These findings underscore tailored efforts in community and clinical settings to reduce at-risk drinking in subgroups with health condition diagnoses.
T-cell engagers (TCE) are cancer immunotherapies that have recently demonstrated meaningful benefit for patients with hematological malignancies and solid tumors. The anticipated widespread use of T cell engagers poses implementation challenges and highlights the need for guidance to anticipate, mitigate, and manage adverse events. By mobilizing T-cells directly at the contact of tumor cells, TCE mount an obligatory and immediate anti-tumor immune response that could result in diverse reactions and adverse events. Cytokine release syndrome (CRS) is the most common reaction and is largely confined to the first drug administrations during step-up dosage. Cytokine release syndrome should be distinguished from infusion related reaction by clinical symptoms, timing to occurrence, pathophysiological aspects, and clinical management. Other common reactions and adverse events with TCE are immune effector Cell-Associated Neurotoxicity Syndrome (ICANS), infections, tumor flare reaction and cytopenias. The toxicity profiles of TCE and CAR-T cells have commonalities and distinctions that we sum-up in this review. As compared with CAR-T cells, TCE are responsible for less frequently severe CRS or ICANS. This review recapitulates terminology, pathophysiology, severity grading system and management of reactions and adverse events related to TCE.
Standardized allergenic extract is intended for use by physicians who are experienced in the administration of standardized (BAU/mL) allergenic extracts for immunotherapy and the emergency care of anaphylaxis, or for use under the guidance of an allergy specialist. For previously untreated patients, the initial dose must be based on skin testing as described in the dosage and administration section of this insert. Standardized Grass Pollen extract is NOT directly interchangeable with Grass Pollen extracts labeled in AU/mL, or with non-standardized Grass Pollen extracts.

This product should not be injected intravenously. Deep subcutaneous routes have proven to be safe. Sensitive patients may experience severe anaphylactic reactions resulting in respiratory obstruction, shock, coma and/or death. (See Adverse Reactions)

Serious adverse reactions should be reported to Nelco Laboratories immediately and a report filed to: MedWatch, The FDA Medical Product Problem Reporting Program, at 5600 Fishers Lane, Rockville, Md. 20852-9787, call 1-800-FDA-1088.

Extreme caution should be taken when using allergenic extracts for patients who are taking beta-blocker medications. In the event of a serious adverse reaction associated with the use of allergenic extracts, patients receiving beta-blockers may not be responsive to epinephrine or inhaled bronchodialators.(1)(See Precautions)

Allergenic extracts should be used with caution in patients with unstable or steroid-dependent asthma or with underlying cardiovascular disease. (See Contraindications)
When the patient has been randomized to either group, a licensed provider under the direction of the PI, will utilize the ultrasound to identify the inferior tibiofibular ligament (syndesmotic ligament). This provider that performs the injection will not be involved in any follow-up visits or return to play review. When appropriate positioning is confirmed, the area will be injected with 5ml of bupivacaine hydrochloride.
n anti-factor IX monoclonal antibody having self-limiting neutralizing activity against Factor IX and the identifying characteristics of SB 249413, SB 249415, SB 249417, SB 257731 or SB 257732 is claimed. Also claimed are an immunoglobulin heavy chain complementary determining region having an amino acid sequence selected from SEQ. ID NO 8, 9 and 10 as defined in the specification and the nucleic acid molecule encoding it. Also claimed are an immunoglobulin light chain complementary determining region having an amino acid sequence selected from SEQ. ID NO 12, 13 and 14 as defined in the specification and the nucleic acid molecule encoding it.   Divisional filed as 501215
Cetrorelix acetate for injection 0.25 mg can be administered by the patient herself after appropriate instructions by her doctor. 

Directions for using Cetrorelix Acetate for Injection 0.25 mg with the enclosed needles and pre-filled syringe:

  1. Wash hands thoroughly with soap and water. 
  2. Flip off the plastic cover of the vial and wipe the aluminum ring and the rubber stopper with an alcohol swab. 
  3. Twist the injection needle with the yellow mark (20 gauge) on the pre-filled syringe. 
  4. Push the needle through the center of the rubber stopper of the vial and slowly inject the solvent into the vial 
  5. Leaving the syringe in the vial, gently swirl the vial until the solution is clear and without residues. Avoid forming bubbles. 
  6. Draw the total contents of the vial into the syringe. If necessary, invert the vial and pull back the needle as far as needed to withdraw the entire contents of the vial. 
  7. Replace the needle with the yellow mark by the injection needle with the grey mark (27 gauge). 
  8. Invert the syringe and push the plunger until all air bubbles have been expelled. 
  9. Choose an injection site in the lower abdominal area, preferably around, but staying at least one inch away from the navel. Choose a different injection site each day to minimize local irritation. Use a second alcohol swab to clean the skin at the injection site and allow alcohol to dry. Gently pinch up the skin surrounding the site of injection. 
  10. Inject the prescribed dose as directed by your doctor, nurse or pharmacist. 
  11. Use the syringe and needles only once. Dispose of the syringe and needles properly after use. If available, use a medical waste container for disposal.
PCT No. PCT/US94/00899 Sec. 371 Date Aug. 28, 1995 Sec. 102(e) Date Aug. 28, 1995 PCT Filed Jan. 26, 1994 PCT Pub. No. WO94/16737 PCT Pub. Date Aug. 4, 1994Methods of inducing genetic material into cells of an individual and compositions and kits for practicing the same are disclosed. The methods comprise the steps of contacting cells of an individual with a polynucleotide function enhancer and administering to the cells, a nucleic acid molecule that is free of retroviral particles. The nucleic acid molecule comprises a nucleotide sequence that encodes a protein that comprises at least one epitope that is identical or substantially similar to an epitope of a pathogen antigen or an antigen associated with a hyperproliferative or autoimmune disease, a protein otherwise missing from the individual due to a missing, non-functional or partially functioning gene, or a protein that produces a therapeutic effect on an individual. Methods of prophylactically and therapeutically immunizing an individual against HIV are disclosed. Pharmaceutical compositions and kits for practicing methods of the present invention are disclosed.
This oil dispersion composition contains water, agar and oil particles. At least a portion of water and the agar form agar gel particles. The average particle diameter of the agar gel particles is 10-150 μm. The average particle diameter of the oil particles is 200-2,000 μm. A plurality of the agar gel particles surround one oil particle. The amount of the agar is 8×10-3 parts by mass or more per part by mass of water.
A method, device, equipment for user grouping, and a non-transitory computer-readable storage medium are provided, which are applicable to the field of medical technology. The method includes the following. Net benefits of multiple users in a target project are obtained. According to the net benefits of the multiple users in the target project and a solution of the target project, a net-benefit coefficient corresponding to the solution is determined. For each grouping variable of the target project, a fluctuation value corresponding to the grouping variable is determined according to the net-benefit coefficient. According to a grouping variable with the largest fluctuation value, the multiple users are divided into multiple user groups. For each user group obtained by division, users in the user group are divided according to a fluctuation value corresponding to each grouping variable of the target project, until a user group meeting a preset condition is obtained.
FIELD: organic chemistry, chemical technology, medicine, pharmacy. SUBSTANCE: invention relates to new derivatives of N,S-substituted N'-1-[(hetero)aryl] -N'-[(hetero)-aryl] methylisothioureas of the general formula (I)   or their salts with pharmacologically acceptable acids HX as racemic mixture or mixture of stereoisomers that can be used for treatment and prophylaxis of diseases associated with dysfunction of glutamatergic neurotransmission. Invention relates also to methods for preparing their salts and bases, pharmaceutical composition, method for treatment and method for study of glutamatergic system. In compounds of the general formula (I) wherein sign (#) means possibility for the presence of chiral carbon atom Y and Z can be similar or different and mean independently aryl or possibly substituted heteroaryl; R 1  means hydrogen atom, lower alkyl, aryl; R 2 -R 3  represent lower alkyl, alkenyl, cycloalkyl, cycloalkenyl and other values indicated in the invention claim. Compounds show ability to inhibit intake of calcium ions stimulated by exciting amino acids taken among glutamic, aspartic acids and their agonist, in particular, that inhibit glutamate-induced uptake of calcium ions by brain cells and therefore eliciting properties of specific neuroprotecting agents. Method for preparing salts of compounds of the formula (I) involves interaction of thiourea with equivalent or excessive amount of corresponding alkylating agent R 3 -G, possibly, in polar inert solvent medium and in the case if alkylating agent is R 3 -OH taken in excess, possibly, in the presence of acid excess, possibly, by effect of microwave-radiation or as homogenized mixture of parent compounds without solvent to yield corresponding salt of (II)   (see scheme). For preparing stable bases neutralization of isothiourea salts in two-phase is carried out. EFFECT: improved preparing method, valuable medicinal properties of compounds. 28 cl, 2 tbl, 21 ex
Conventional motivation procedures associated with 3D intra oral procedures. A 3D intra-oral modelization will added to the previously described procedure. Then, a periodontist will show the sites contaminated by dental plaque to the patient.
One hundred and forty eight patients with chronic low back pain from two outpatient physiotherapy clinics in Brazil will be randomized to receive either Cognitive Functional Therapy or combined Manual Therapy and Motor Control Exercises. Intervention: 4-10 sessions of CFT. Control: 4-10 sessions of combined Manual Therapy and Motor Control Exercises. Measurements: Clinical outcomes will be assessed at the baseline, 3 months, 6 months and 12 months after randomization. Analysis: Intention-to-treat analysis will be performed, and linear mixed models will be calculated to evaluate the effect of the intervention. Non-specific predictors, moderators and mediators of outcome will also be analysed. Discussion: This study will investigate whether the results of the first CFT clinical trial can be replicated. In addition, the results will contribute to a better understanding of the efficacy of the CFT approach.
All participants have habitual Comfilcon A Toric lenses optimized for wear over 2 weeks. Then all participants are fit with the Verofilcon A study daily disposable lenses with water surface treatment for astigmatism.
Cardiac allograft vasculopathy (CAV) is a major cause of morbidity and mortality following heart transplantation (HT). Prior studies identified distinct CAV trajectories in the early post-HT period with unique predictors, but the evolution of CAV in later periods is not well-described. This study assessed the prevalence of late CAV progression and associated risk factors in HT recipients with ISHLT CAV 0/1 at 10 years post-HT. Consecutive adult patients who underwent HT from January 2000 to December 2008 were evaluated and grouped by CAV trajectories into progressors (developed ISHLT CAV 2/3) or nonprogressors (remained ISHLT CAV 0/1). A total of 130 patients were included with a median age at angiography of 61.7 years and a median follow-up time of 4.8 years. 8.5% progressed to CAV 2/3, while the remaining 91.5% were nonprogressors. Progression was not associated with death or retransplantation (27.3% [progressor] vs. 21.0% [nonprogressor], p = 0.70). These data may inform shared decision-making about late CAV screening.
The present disclosure provides a method for chemoselective modification of a target molecule. A subject method includes contacting a target molecule comprising a thiol moiety with a biomolecule comprising a reactive moiety, wherein the reactive moiety is generated by reaction of a biomolecule comprising a phenol moiety or a catechol with an enzyme capable of oxidizing the phenol or the catechol moiety. The contacting is carried out under conditions sufficient for conjugation of the target molecule to the biomolecule, thereby producing a modified target molecule. The present disclosure provides compositions comprising a subject target molecule comprising a thiol moiety, and a biomolecule comprising a phenol moiety or a catechol moiety. The present disclosure provides kits for carrying out a subject method. The present disclosure also provides modified target molecules and methods for using same.
The invention provides a composite phospholipid transfersome which promotes propranolol percutaneous absorption, and a preparation method thereof. According to the invention, two phospholipid materials with different phase-change temperatures, which are dipalmitoyl phosphatidyl choline and soybean lecithin, are adopted as a composite phospholipid material. Compared with a transfersome with a single phospholipid material in prior art, the propranolol composite phospholipid transfersome prepared with the phospholipid material provided by the invention has substantially improved encapsulation efficiency, reduced leakage, improved stability in rat plasma, and substantially improved bioavailability after percutaneous administration. The propranolol composite phospholipid transfersome provided by the invention is especially suitable to be used for treating infantile hemangioma. With the transfersome, propranolol percutaneous administration can be realized, and propranolol can directly act upon a hemangioma affected part. The treatment effect is improved, toxic and side effects are reduced, and children medication compliance can be improved. Also, the invention provides a preparation method of the propranolol composite phospholipid transfersome.
This document relates to methods and materials for assessing and/or treating mammals ( e.g. , humans) having melanoma ( e.g. , primary cutaneous melanoma (PCM)). For example, methods and materials that can be used to determine whether or not a melanoma is likely to relapse ( e.g. , likely to relapse following treatment) are provided. For example, methods and materials for treating a mammal ( e.g. , a human) having melanoma where the treatment is selected based, at least in part, on whether or not the melanoma is likely to relapse are provided.